Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001)

NCT01508156 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: IDX719
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC